Interpace Biosciences (IDXG) Announces Impending Delisting from Nasdaq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Interpace Biosciences Announces Impending Delisting from Nasdaq
February 17, 2021 8:00 AM ESTPARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (Interpace or the Company), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) that the Staff has determined to delist the Companys securities from Nasdaq. This determination was due to the Companys extended period of non-compliance with the minimum $2,500,000 stockholders equity requirement for continued listing set forth in listing Rule 5550(b) and the Companys failure to timely execute on its plan to... More
